Unmet Horizons: Assessing the Challenges in the Treatment of TP53 -Mutated Acute Myeloid Leukemia

Acute myeloid leukemia (AML) remains a challenging hematologic malignancy. The presence of mutations in AML poses a therapeutic challenge, considering that standard treatments face significant setbacks in achieving meaningful responses. There is a pressing need for the development of innovative treatment modalities to overcome resistance to conventional treatments attributable to the unique biology of -mutated ( ) AML. This review underscores the role of mutations in AML, examines the current landscape of treatment options, and highlights novel therapeutic approaches, including targeted therapies, combination regimens, and emerging immunotherapies, as well as agents being explored in preclinical studies according to their potential to address the unique hurdles posed by AML.